title: Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma.
abstract: BACKGROUND
  Outcomes for patients with metastatic Ewing sarcoma (ES) remain poor. We investigated whether the intensification of ifosfamide improved survival for patients with metastatic ES.
  
  
  METHODS
  We conducted a retrospective chart review of 30 patients with metastatic ES treated with the MSKCC "EFT regimen." The regimen included an intensification of ifosfamide dosing from 1,800 mg/m(2) /day × 5 days per cycle to 2,800 mg/m(2) /day × 5 days per cycle.
  
  
  RESULTS
  Twenty six of the 30 patients completed planned chemotherapy. Two patients experienced disease progression during therapy. There were no toxic deaths. One patient developed secondary leukemia. The 4-year event free survival (EFS) was 27% and the overall survival (OS) was 39%.
  
  
  CONCLUSIONS
  Intensification of ifosfamide was tolerated and did not increase toxicity in patients with metastatic ES. The intensification did not improve outcomes for these patients with metastatic disease.
authors: Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York.
authors: Heather
authors: H
authors: Magnan
authors: Christine M
authors: CM
authors: Goodbody
authors: Elyn
authors: E
authors: Riedel
authors: Christine A
authors: CA
authors: Pratilas
authors: Leonard H
authors: LH
authors: Wexler
authors: Alexander J
authors: AJ
authors: Chou
mesh_terms: D000293:Adolescent; D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D002648:Child; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D009362:Neoplasm Metastasis; D012512:Sarcoma, Ewing / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D015996:Survival Rate; D013997:Time Factors
chemical_list: D018906:Antineoplastic Agents, Alkylating; D007069:Ifosfamide
keywords: Ewing sarcoma; chemotherapy; outcomes
references: J Clin Oncol. 2000 Sep;18(17):3108-14
references: 10963639
references: N Engl J Med. 2003 Feb 20;348(8):694-701
references: 12594313
references: J Clin Oncol. 2003 Sep 15;21(18):3423-30
references: 12972518
references: Cancer. 1990 Sep 1;66(5):887-93
references: 2201433
references: J Clin Oncol. 1995 Nov;13(11):2796-804
references: 7595741
references: Semin Oncol. 1997 Aug;24(4 Suppl 10):S10-3-S10-10
references: 9275000
references: Ann Oncol. 1998 Mar;9(3):275-81
references: 9602261
references: Acta Oncol. 2006;45(4):469-75
references: 16760184
references: Cancer. 2007 Jul 15;110(2):375-84
references: 17569105
references: Pediatr Blood Cancer. 2007 Dec;49(7):894-900
references: 17584910
references: J Pediatr Hematol Oncol. 2008 Jun;30(6):425-30
references: 18525458
references: J Clin Oncol. 2012 Nov 20;30(33):4148-54
references: 23091096